PO0071 - Real World Data : Safety and Mortality Monitoring the patients on Rivaroxaban in our center

Background: Direct Oral anticoagulants (DOACs) have been approved for stroke prevention in non-valvular atrial fibrillation (AF).
The outcomes achieved by clinical trials depend on pharmacokinetics and pharmacodynamics of these drugs which are used orally in regular doses once or twice.
During our practice we need to evaluate the safety profile as well as the efficacy of Rivaroxaban in our cardiac center.
Real world data is required in different part in the world, No enough information are available in matter of patient on Rivaroxaban a direct factor Xa inhibitor specially in Saudi population

Aims: This study will be the first in Saudi Arabia to give an idea about current practice being used at anticoagulant clinic and criteria used to choose patients were switched to Rivaroxaban, to evaluate the safety & efficacy also. Evaluate the effectiveness and safety of DOACs which is Rivaroxaban for stroke prevention in Non-Valvular atrial fibrillation.

Methods: An observational retrospective study in university tertiary hospital in Saudi Arabia, 326 patient’s non-valvular atrial fibrillation on DOACs Rivaroxaban (2015-2021)
Laboratory 1 year follow ups for each patient who was on Rivaroxaban
Follow up any thrombotic or bleeding events during their treatment plans.
CRF form has been validated by the Team.

Results: No significant deferent in the stroke and bleeding events between our data and the global data.
as the pharmacokinetics and pharmacodynamic of Rivaroxaban in Saudi patients almost similar to the global ones and so the real world data show's similarity in this part.

Conclusion(s): The data shows that the DOAC Rivaroxaban are effective and safe to be used for Non-Valvular atrial fibrillation regardless the dose of anticoagulant,
Further studies are needed to support these findings in other cardiac centers